Sign In
Buy SNY
$43.75
-0.230 (-0.523%)
At Close: Jul 21, 2026
Sanofi: Reliance On One Drug Strategy May Bite
02:29am, Friday, 27'th May 2022
Sanofi's strong reliance on a single product Dupixent poses risks as competition in atopic dermatitis segment increases. It struggled to show any superiority in COVID-19 vaccine development and is sti
Why Regeneron Investors Shouldn't Fear Its Patent Cliff
11:42am, Thursday, 26'th May 2022 The Motley Fool
New treatments will step in to replace blockbuster eye medication EYLEA.
Biotech Stock Roundup: ETTX Up on Acquisition Deal, REGN Offers Updates
02:06pm, Wednesday, 25'th May 2022 Zacks Investment Research
Regulatory updates and acquisition news from Entasis (ETTX) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.
Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication (Revised)
05:09am, Wednesday, 25'th May 2022 Zacks Investment Research
The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.
Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication (Revised)
03:16am, Wednesday, 25'th May 2022
The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.
The Zacks Analyst Blog Highlights Alphabet, UnitedHealth Group, Costco Wholesale, Cisco Systems and Sanofi
09:34am, Tuesday, 24'th May 2022 Zacks Investment Research
Alphabet, UnitedHealth Group, Costco Wholesale, Cisco Systems and Sanofi have been included in this Analyst Blog.
Top Stock Reports for Alphabet, UnitedHealth & Costco
04:29pm, Monday, 23'rd May 2022 Zacks Investment Research
Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), UnitedHealth Group Incorporated (UNH), and Costco Wholesale Corporation (COST).
Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication
02:20pm, Monday, 23'rd May 2022 Zacks Investment Research
The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.
Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication
12:03pm, Monday, 23'rd May 2022
The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.
This Safe Stock Is Dirt Cheap -- and It's Beating the Market
12:03pm, Friday, 20'th May 2022 The Motley Fool
There's a lot to like about this big pharma juggernaut.
This Safe Stock Is Dirt Cheap -- and It's Beating the Market
08:03am, Friday, 20'th May 2022
There's a lot to like about this big pharma juggernaut.
Sanofi ordered to compensate French family for epilepsy drug side effects
07:53am, Saturday, 14'th May 2022
A French court has ordered Sanofi to pay more than 400,000 euros ($416,440) in damages to a family whose child suffered from a form of autism caused by its epilepsy drug Valproate, saying the drugmake
Regulus (RGLS) Up as FDA Accepts IND for Kidney Disease Drug
02:20pm, Thursday, 12'th May 2022 Zacks Investment Research
The FDA accepts Regulus' (RGLS) IND application for RGLS8429 to treat autosomal dominant polycystic kidney disease. The company plans to begin a phase I study in second-quarter 2022. Stock up.
How Novo Nordisk Will Protect Insulin Sales
11:23am, Thursday, 12'th May 2022 The Motley Fool
Advancing insulin technology promises a better patient experience.
Is Dario (DRIO) Health Eating Teladoc's (TDOC) Lunch? Q1 Earnings on Tap Thursday After Meeting with Sanofi (SNY)
01:35pm, Wednesday, 11'th May 2022
Teladoc (NYSE: TDOC) stock recently cratered to a new 52 week low following it's Q1 report. Some of it's shortfall was attributed by management to longer sales cycles in the insurer and employer space
